

Asst. Prof. MERVE DEMİRBÜĞEN ÖZ

Personal Information

Office Phone: [+90 312 230 3121](tel:+903122303121)

Email: demirbugen@ankara.edu.tr

Web: <https://avesis.ankara.edu.tr/demirbugen>

International Researcher IDs

ORCID: 0000-0002-8484-1207

ScopusID: 57203908915

Yoksis Researcher ID: 204184

Education Information

Post Doctorate, The University of Nottingham, England 2022 - 2023

Doctorate, Ankara University, Sağlık Bilimleri Enstitüsü, Farmasötik Toksikoloji (Dr) (Eczacılık), Turkey 2014 - 2019

Undergraduate, Ankara University, Eczacılık Fakültesi, Eczacılık Pr., Turkey 2007 - 2013

Dissertations

Doctorate, Takrolimus Kullanan Böbrek Nakil Hastalarında Farmakogenetiğin Öneminin Araştırılması, Ankara University, Sağlık Bilimleri Enstitüsü, Farmasötik Toksikoloji (Dr) (Eczacılık), 2019

Research Areas

Pharmaceutical Toxicology

Academic Titles / Tasks

Research Assistant, Ankara University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, 2014 - Continues

Courses

Etkin İlaç Kullanımında Genetik Faktörler, Undergraduate, 2020 - 2021

Çevre Ve Endüstriyel Kirlenmelerin İnsan Sağlığına Etkileri , Undergraduate, 2021 - 2022

Genetic Factors in Efficient Drug Use, Undergraduate, 2020 - 2021

The Effects of Environmental and Industrial Pollutants on Human Health, Undergraduate, 2021 - 2022

İlaç ve Zehir Bilgisi, Associate Degree, 2020 - 2021

Published journal articles indexed by SCI, SSCI, and AHCI

1. The effects of UGT1A4 and ABCB1 polymorphisms on clozapine and N- desmethyl clozapine plasma levels in Turkish schizophrenia patients.

Ozdemir F., Oz M. D., Tok K. C., Dural E., Kir Y., Gumustas M., Baskak B., Suzen H. S.

Toxicology and applied pharmacology, pp.117219, 2025 (SCI-Expanded)

- II. **The role of tissue persistent organic pollutants and genetic polymorphisms in patients with benign and malignant kidney tumors**
KOCAGÖZ R., Onat I., Oz M., Turna B., Kumbaraci B. S., ORMAN M. N., SÜZEN H. S., ORHAN H.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, vol.110, 2024 (SCI-Expanded)
- III. **Blood and tissue levels of persistent organic pollutants and genetic susceptibility in patients with breast cancer**
Onat I., Kocagöz R., DEMİR BÜĞEN ÖZ M., Yeniay L., Tiftikçiöğlü Y. Ö., Zekioğlu O., Serin G., Özdemir M., Gür E., SÜZEN H. S., et al.
Environmental Toxicology and Pharmacology, vol.108, 2024 (SCI-Expanded)
- IV. **Dysregulation of RNA modification systems in clinical populations with neurocognitive disorders**
Knight H. M., Öz M., PerezGrovas-Saltijeral A.
Neural Regeneration Research, vol.19, no.6, pp.1256-1261, 2024 (SCI-Expanded)
- V. **Assessment of Genetic and Lifestyle Factors on Clozapine and N-desmethylclozapine Plasma Levels in Schizophrenia Patients**
Demirbüğen Öz M., Özdemir F., Tok K. C., Dural E., Kir Y., Ulusoy M., Gümüştas M., Baskak B., Süzen H. S.
PHARMACOPSYCHIATRY CLINICAL PHARMACOLOGY, PSYCHIATRY, PSYCHOLOGY, NEUROPHYSIOLOGY, NEUROBIOLOGY, GERONTOPSYCHIATRY, vol.57, no.2, pp.87, 2024 (SCI-Expanded)
- VI. **Global Co-regulatory Cross Talk Between m6A and m5C RNA Methylation Systems Coordinate Cellular Responses and Brain Disease Pathways**
Orji O. C., Stones J., Rajani S., Markus R., öz M., Knight H. M.
Molecular Neurobiology, 2024 (SCI-Expanded)
- VII. **The Potential Role of *POR*28* and *CYP1A2*F* Genetic Variations and Lifestyle Factors on Clozapine and N-Desmethylclozapine Plasma Levels in Schizophrenia Patients**
Demirbüğen Öz M., Ozdemir F., Tok K. C., Dural E., Kir Y., Ulusoy M., Gümüştas M., Baskak B., Süzen H. S.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, vol.19, no.5, pp.319-327, 2023 (SCI-Expanded)
- VIII. **Association between superoxide dismutase 2, glutathione peroxidase 1, xeroderma pigmentosum group d gene variations, and head and neck squamous cell cancer susceptibility**
Kose G., Oz M., CÖMERT E., SÜZEN H. S.
ARCHIVES OF BIOLOGICAL SCIENCES, vol.74, no.2, pp.181-189, 2022 (SCI-Expanded)
- IX. **The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants**
DEMİR BÜĞEN ÖZ M., Ozdemir F., SÜZEN H. S.
Current drug metabolism, vol.22, no.8, pp.596-627, 2021 (SCI-Expanded)
- X. **The role of COMT polymorphism in modulation of prefrontal activity during verbal fluency in bipolar disorder**
Devrimci-Ozguven H., Alici Y. H., DEMİR BÜĞEN ÖZ M., SÜZEN H. S., Kale H. E., Baskak B.
NEUROSCIENCE LETTERS, vol.738, 2020 (SCI-Expanded)
- XI. **Association between serotonin 2A receptor (HTR2A), serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients**
DEMİR BÜĞEN ÖZ M., BASKAK B., UÇKUN Z., Artun N. Y., Ozdemir H., Ozel T. K., ÖZGÜVEN H., SÜZEN H. S.
PHARMACOGENOMICS JOURNAL, vol.20, no.3, pp.443-450, 2020 (SCI-Expanded)
- XII. **A Novel PCR-RFLP Method for Detection of POR*28 Polymorphism and its Genotype/Allele Frequencies in a Turkish Population**
Ozdemir F., DEMİR BÜĞEN ÖZ M., SÜZEN H. S.
CURRENT DRUG METABOLISM, vol.20, no.10, pp.845-851, 2019 (SCI-Expanded)
- XIII. **The relationship between the serotonin 2A receptor gene-1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients**
DEMİR BÜĞEN ÖZ M., UÇKUN Z., Yuce-Artun N., BASKAK B., Ozdemir H., Ozel T. K., ÖZGÜVEN H., SÜZEN H. S.

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.33, no.5, 2018 (SCI-Expanded)

XIV. The effect of additional noradrenergic and serotonergic depletion on a lateralised choice reaction time task in rats with nigral 6-OHDA lesions

Lindgren H. S., Demirbügen M., Bergqvist F., Lane E. L., Dunnett S. B.
Experimental Neurology, vol.253, pp.52-62, 2014 (SCI-Expanded)

Articles Published in Other Journals

I. THE COMPARISON OF ANTIOXIDANT AND ANTIBACTERIAL ACTIVITY OF NOVEL PYRIMIDO[1,2-a]PYRIMIDINE COMPOUNDS

BAYRAMOĞLU D., DEMİRBÜĞEN ÖZ M., KIYMACI M. E.
Ankara Üniversitesi Eczacılık Fakültesi Dergisi, vol.47, no.1, pp.1-8, 2023 (Scopus)

Books & Book Chapters

I. Çevresel kimyasallara maruziyet ve epigenetik

DEMİRBÜĞEN ÖZ M.

in: CUMHURİYETİN 100. YILINDA ECZACILIKTA YENİLİKLER 4, Asuman Bozkır, İlkay Yıldız, Editor, Ankara Üniversitesi Yayınları, pp.537-550, 2023

II. Major Depresyonda Bireyselleştirilmiş Tedavi ve Farmakogenetiğin Önemi

DEMİRBÜĞEN ÖZ M., SÜZEN H. S.

in: Eczacılıkta Yenilikler 3, Özçelikay Gülbin, Yıldız İlkay, Editor, Ankara Üniversitesi Yayınları, Ankara, pp.447-456, 2020

III. Radyasyon ve radyoaktif materyallerin toksik etkileri

DEMİRBÜĞEN M., ÜSTÜNDAĞ A., ÜLKER Ö., UÇKUN Z., YILMAZ SARIALTIN S.

in: Casarett and Doull's Toksikolojinin Temelleri, Sinan Süzen, Ahmet Oğuz Ada, Bulut Demirel, Onur Erdem, Gonca Çakmak Demircigil, Pınar Erkekoğlu, Editor, Nobel Tıp Kitabevi, Ankara, pp.373-380, 2017

Refereed Congress / Symposium Publications in Proceedings

I. Assessment of Genetic and Lifestyle Factors on Clozapine and N-desmethylozapine Plasma Levels in Schizophrenia Patients

Demirbügen Öz M., Özdemir F., Tok K. C., Dural E., Kır Y., Ulusoy M., Gümüştas M., Baskak B., Süzen H. S.

XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP, Freiburg, Germany, 20 - 22 March 2024, pp.87

II. IN SILICO MOLECULAR PATHWAY IDENTIFICATION OF CROHN'S DISEASE REGARDING THE POTENTIAL EFFECT OF ENDOCRINE DISRUPTING BISPHENOL A

DEMİRBÜĞEN ÖZ M.

EURO ASIA 11. INTERNATIONAL CONGRESS ON APPLIED SCIENCES, Turkey, 27 May 2023

III. EVALUATION OF THE POTENTIAL INFLUENCE OF CADMIUM ON MOLECULAR MECHANISMS IN THE OCCURRENCE OF PROSTATE CANCER THROUGH DATA-MINING

DEMİRBÜĞEN ÖZ M.

EURO ASIA 11. INTERNATIONAL CONGRESS ON APPLIED SCIENCES, Turkey, 27 May 2023

IV. THE IMPACT OF THE CYTOCHROME P450 3A4 (CYP3A4*22) POLYMORPHISM ON TACROLIMUS DOSE REQUIREMENTS AND EXPOSURE DURING EARLY PERIOD FOLLOWING KIDNEY TRANSPLANTATION

DEMİRBÜĞEN ÖZ M., KEVEN K., SÜZEN H. S.

13th International Symposium on Pharmaceutical Sciences (ISOPS), Ankara, Turkey, 22 - 25 June 2021

V. IDENTIFYING POTENTIAL GENETIC BIOMARKERS OF THE CARDIOTOXICITY INDUCED BY

ANTHRACYCLINES

DEMİRBUĞEN ÖZ M.

13th International Symposium on Pharmaceutical Sciences (ISOPS), Ankara, Turkey, 22 - 25 June 2021

- VI. **USEFUL PHARMACOGENETIC BIOMARKERS IN CHILDHOOD CANCER TREATMENT AND ADVERSE DRUG REACTIONS**
DEMİRBUĞEN ÖZ M.
7. INTERNATIONAL GEVHER NESİBE HEALTH SCIENCES CONFERENCE, Kayseri, Turkey, 16 - 17 April 2021
- VII. **THE IMPORTANCE OF THE CYTOCHROME P450 3A5 (CYP3A5*3) POLYMORPHISM ON TACROLIMUS DOSE REQUIREMENTS AND TROUGH LEVELS DURING EARLY PERIOD AFTER KIDNEY TRANSPLANTATION**
DEMİRBUĞEN ÖZ M., KEVEN K., SÜZEN H. S.
2nd INTERNATIONAL CONGRESS OF MULTIDISCIPLINARY STUDIES IN MEDICAL SCIENCES, Ankara, Turkey, 13 - 14 February 2021
- VIII. **The role of genetic and epigenetic factors in major depressive disorder**
DEMİRBUĞEN ÖZ M., SÜZEN H. S.
5th International Congress on Epigenetics Chromatin, Viyana, Austria, 22 - 23 August 2019
- IX. **The Role of Comt Polymorphisms in Modulation of Prefrontal Activity During Verbal Fluency in Bipolar Disorder**
HOŞGÖREN Y., DEVRİMCİ ÖZGÜVEN H., BASKAK B., DEMİRBUĞEN ÖZ M., SÜZEN H. S., DUMAN B.
Bipolar Bozukluklar Derneği Bipolar Bozukluk Araştırmacı Klinisyen Eğitim Toplantısı (BAKET), Turkey, 15 - 16 September 2018
- X. **THE POSSIBLE ASSOCIATION BETWEEN BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) GENETIC POLYMORPHISM VAL66MET AND SUSCEPTIBILITY TO BIPOLAR DISORDERS (BPD)**
DEMİRBUĞEN ÖZ M., HOŞGÖREN Y., DUMAN B., BASKAK B., DEVRİMCİ ÖZGÜVEN H., SÜZEN H. S.
12th International Symposium on Pharmaceutical Sciences (ISOPS-12), 26 - 29 June 2018
- XI. **THE 5-HYDROXYTRİPTAMINE 2A RECEPTOR -1438A/G AND 102T/C POLIMORPHISMS AND NAUSEA SIDE EFFECT IN CITALOPRAM TREATED MAJOR DEPRESSIVE DISORDER PATIENTS**
DEMİRBUĞEN ÖZ M., UÇKUN Z., YÜCE ARTUN N., DEVRİMCİ ÖZGÜVEN H., SÜZEN H. S.
12th International Symposium on Pharmaceutical Sciences, 26 - 29 June 2018
- XII. **THE RELATIONSHIP BETWEEN THE DIFFERENT GENETIC POLYMORPHISMS AND METHYLPHENIDATE INDUCED ADVERSE DRUG REACTIONS IN ATTENTION DEFICIT HYPERACTIVITY DISORDER PATIENTS**
DEMİRBUĞEN M., SÜZEN H. S.
1st International Food and Medicine Congress, 24 - 27 May 2018
- XIII. **COMMON GENE POLYMORPHISMS IN ANTIOXIDANT ENZYME SYSTEMS AND ITS RELATION WITH THE NUTRION**
DEMİRBUĞEN M., SÜZEN H. S.
1st International Food and Medicine Congress, 24 - 27 May 2018
- XIV. **Kidney, breast and stomach cancers in relation to internal concentrations of persistent organic pollutants, DNA damage markers and related polymorphisms**
ORHAN H., SÜZEN H. S., KOCAGÖZ R., ONAT İ., DEMİRBUĞEN ÖZ M., TURNA B., ATILA K., YENİAY L., SARSIK KUMBARACI B., ZEKİOĞLU O., et al.
The 10th Congress of the Toxicology in Developing Countries (CTDC10th), 17 - 22 April 2018, vol.4, pp.18
- XV. **Aspirin Kullanımı Ve Kolesterol Değerleri Arasındaki İlişki**
Demirel B., DEMİRBUĞEN M.
9th Asian Conference on Emergency Medicine and 13th Turkish Emergency Medicine Congress, 22 - 25 November 2017
- XVI. **The Serotonin 2A Receptor Gene -1438A/G Polymorphism and Sertraline Induced Nausea in Major Depressed Turkish Patients**
DEMİRBUĞEN M., UÇKUN Z., SÜZEN H. S.
2nd International Gazi Pharma Symposium Series(GPSS-2017), Ankara, Turkey, 11 - 13 October 2017
- XVII. **Sitalopram kullanan major depresyon hastalarında bulantı/kusma advers etkisinin serotonin-2A**

reseptör geni -1438A/G polimorfizmi ile ilişkisinin incelenmesi

DEMİR BÜĞEN M., SÜZEN H. S.

1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu, Turkey, 1 - 02 June 2017

XVIII. Antipsychotic Drugs and the Risk of Sudden Cardiac Death

DEMİR BÜĞEN M., SÜZEN H. S.

The 2nd International Congress and Workshop of Forensic Toxicology, 26 - 30 May 2016

XIX. 5 HT2A receptor 102T C polymorphism and incidence of nausea induced by sertraline treatment

DEMİR BÜĞEN M., UÇKUN Z., YÜCE N., BASKAK B., SÜZEN H. S.

Türk Heltox Toxicology Congress, 21 - 24 October 2015

XX. THE ASSOCIATION OF SEROTONINE 2A RECEPTOR 102 T/C POLYMORPHISM AND NAUSEA IN CITALOPRAM TREATED PATIENTS

DEMİR BÜĞEN M., BASKAK B., Devrimci Özgüven H., Kızıl Özel T., SÜZEN H. S.

11th International Symposium on Pharmaceutical Sciences, 9 - 12 June 2015

XXI. The association of serotonin 2A receptor 102T C polymorphism and nausea in citalopram treated patients

DEMİR BÜĞEN M., BASKAK B., ÖZEL KIZIL E. T., ÖZGÜVEN H., SÜZEN H. S.

11th International Symposium on Pharmaceutical Sciences, 9 - 12 June 2015

XXII. Toxicology, Pharmacology, Detection and Legal Status of Synthetic Cannabinoids

YILMAZ S., DEMİR BÜĞEN M., YALÇIN C. Ö.

1st International Congress and Workshop of Forensic Toxicology, 29 - 30 November 2014

XXIII. The effect of additional noradrenergic and serotonergic depletion on lateralised choice reaction time task in rats with nigral 6-OHDA lesions

DEMİR BÜĞEN ÖZ M., Lindgren H. S., Lane E. L.

50th Congress of the European-Societies-of-Toxicology, Edinburgh, Saint Helena, 7 - 10 September 2014, vol.229

XXIV. 6-OHDA İLE UNİLATERAL LEZYON OLUŞTURULAN SIÇANLARDA SEROTONİN, NORADRENALİN VE DOPAMİNİN MOTOR ÖĞRENME KABİLİYETİ ÜZERİNE ETKİSİ

DEMİR BÜĞEN M., Lindgren H., Lane E.

III. Türk Toksikoloji Derneği Sempozyumu, Turkey, 12 - 14 June 2014

Metrics

Publication: 42

Citation (WoS): 29

Citation (Scopus): 36

H-Index (WoS): 3

H-Index (Scopus): 3